Deadly brain cancer stopped with new compound

4th International Conference on Neurology and Healthcare

Deadly brain cancer stopped with a new compound

Abstract submission @ https://neurology.cmesociety.com/abstract-submission 

Glioblastoma, one of the deadliest forms of brain cancer, may have found its nemesis. New research shows that a tumour, which is notoriously difficult to treat, can be halted by an experimental compound.

New research shows that an experimental compound can stop aggressive brain tumours from growing.

Glioblastoma is a particularly aggressive form of a brain tumour, with a median survival rate of 10–12 months.
Part of the reason why glioblastomas are so deadly is that they arise from a type of brain cell called astrocytes.
These cells are shaped like a star, so when the tumours form they develop tentacles, which makes them difficult to remove surgically.

Additionally, the tumours advance rapidly. This is because astrocytes provide support to neurons and control the amount of blood that reaches them; so, when tumours form, they have access to a large number of blood vessels, helping cancerous cells to grow and spread very quickly.
Another reason that glioblastomas are so difficult to treat is their high rate of recurrence.

 This is partly due to a subpopulation of cells contained in a tumour called glioma stem cells (GSC) — a type of self-regenerating cancer stem cell that controls the growth of tumours.

Subhas Mukherjee, Ph.D., a research assistant professor of pathology at the Northwestern University Feinberg School of Medicine in Chicago, IL, and his colleagues have been studying the behaviour of these cells for a few years. Building on this previous research, Mukherjee and team have now found that these cells contain high levels of an enzyme called CDK5.

Blocking this enzyme, the researchers show in their new study, stops glioblastomas from growing and inhibits the self-regenerating capabilities of GSCs.

The findings were published in the journal Cell Reports.